Genetic Information, Genomic Technologies, and the Future of Drug Discovery

Bumol, Thomas F.; Watanabe, August M.

doi:10.1001/jama.285.5.551

Cited by 40 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nearly 300 tests based on direct analysis of DNA sequences are available for clinical use as of March 2001, even if their clinical validity and utility remain to be fully established [Grody and Pyeritz, 1999;GeneTests, 2001]. The development of new drugs is being enhanced by genomic and proteomic approaches and the ability to tailor treatments and predict both positive and negative outcomes through the analysis of patient genotypes is in its infancy [Roses, 2000;Bumohl and Watanabe, 2001]. As many have suggested, the health professions are in the early stages of revolutionary change based on the incorporation of a genetics perspective [Pyeritz, 1992;Childs, 1999;Chakravarti, 2001] and virtually no specialty of medicine will remain unaffected.…”

Section: Introductionmentioning

confidence: 99%

Empowering primary care health professionals in medical genetics: How soon? How fast? How far?

2001

View full text Add to dashboard Cite

Applications of genetics to the practices of medicine and public health are important today and will only become more compelling as our understanding of the human genome evolves. Because of a perceived lack of medical genetics professionals, it is generally believed that primary health care providers (PCPs) will need to assume prominent roles in delivering clinical genetics services. However, a number of studies indicate that most PCPs are neither well enough educated in genetics nor interested enough in becoming so to effectively contribute. Those who advocate empowering PCPs must be aware of potential problems with any approach thus far suggested for achieving this goal. Moreover, any analysis of this model must consider the potential ramifications for medical genetics professionals, patients, and families. In this article, we explore some of the unique features of the culture of medical genetics services and service providers. We discuss how important this culture is to clinical outcomes and the likelihood that its positive attributes would be preserved in a PCP model of medical genetics service delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Empowering primary care health professionals in medical genetics: How soon? How fast? How far?

2001

View full text Add to dashboard Cite

show abstract

“…Successful drug treatments of the past and present involve fewer than 500 targets including growth factors and cytokines as of 1996 (Bumol and Watanabe, 2001). It is assumed that at least 5000 of the possible 120,000 proteins may be potential therapeutic proteins or targets, suggesting that only 10% of potential therapeutic strategies have been identified and exploited to date (Drews, 2000).…”

Section: Discussionmentioning

confidence: 99%

A System Biology Approach to Bioinformatics and Functional Genomics in Complex Human Diseases: Arthritis

Attur

Dave

Tsunoyama³

et al. 2002

Current Issues in Molecular Biology

View full text Add to dashboard Cite

Human and other annotated genome sequences have facilitated generation of vast amounts of correlative data, from human/animal genetics, normal and disease-affected tissues from complex diseases such as arthritis using gene/protein chips and SNP analysis. These data sets include genes/proteins whose functions are partially known at the cellular level or may be completely unknown (e.g. ESTs). Thus, genomic research has transformed molecular biology from "data poor" to "data rich" science, allowing further division into subpopulations of subcellular fractions, which are often given an "-omic" suffix. These disciplines have to converge at a systemic level to examine the structure and dynamics of cellular and organismal function.The challenge of characterizing ESTs linked to complex diseases is like interpreting sharp images on a blurred background and therefore requires a multidimensional screen for functional genomics ("functionomics") in tissues, mice and zebra fish model, which intertwines various approaches and readouts to study development and homeostasis of a system. In summary, the post-genomic era of functionomics will facilitate to narrow the bridge between correlative data and causative data by quaint hypothesis-driven research using a system approach integrating "intercoms" of interacting and interdependent disciplines forming a unified whole as described in this review for Arthritis.

show abstract

“…Historically, a small number of gene families that include GPCRs, ion channels, proteases, kinases, nuclear hormone receptors, cytokines, adhesion molecules, and phosphatases are enriched for these ''druggable'' targets. In addition, secreted hormones, soluble receptors, and decoys may serve either as drug substances or as potential targets by other biological methods [Bumol and Watanabe, 2001].…”

Section: G Protein-coupled Receptors As Potential Targets For Drug DImentioning

confidence: 99%

Computational identification and analysis of G protein‐coupled receptor targets

Feng

Jiang

2006

Drug Development Research

View full text Add to dashboard Cite

The completion of the human genome sequence has provided a large pool of potential drug targets for disease therapy. G protein–coupled receptors (GPCRs), which are central to signaling networks that regulate basic cellular processes, represent the most important known class of therapeutic targets for multiple disease states. Bioinformatics approaches can be applied to facilitate the identification of novel GPCRs, understanding their physiological and pathological roles, and screening for drug discovery. The present review summarizes current bioinformatics approaches that can be used to identify and analyze GPCR targets. In addition, the limitations of these technologies with the intention of setting reasonable expectations are also discussed together with some potential avenues for GPCR research. Drug Dev. Res. 67:771–780, 2006. © 2007 Wiley‐Liss, Inc.

show abstract

Genetic Information, Genomic Technologies, and the Future of Drug Discovery

Cited by 40 publications

References 46 publications

Empowering primary care health professionals in medical genetics: How soon? How fast? How far?

Empowering primary care health professionals in medical genetics: How soon? How fast? How far?

A System Biology Approach to Bioinformatics and Functional Genomics in Complex Human Diseases: Arthritis

Computational identification and analysis of G protein‐coupled receptor targets

Contact Info

Product

Resources

About